VC: FoldRX lands $43M in VC
FoldRX lands $43M in VC
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
FoldRx Pharmaceuticals
|
$43M
|
Texas Pacific Group Ventures and Alta Partners |
The funding will support clinical trials for FoldRx's lead drug compound, Fx-1006A, which is finishing an early-stage trial to treat diseases of protein misfolding in the brain or heart. |
|
Lux Biosciences
|
$36M
|
HBM Partners AG, Novo A/S, and SV Life Sciences |
Isotechnika has grated Lux rights to develop and commercialize Isotechnika's Phase III product candidate ISA247 for the treatment and prophylaxis of all ophthalmic diseases. |
|
U3 Pharma
|
$34M
|
Life Sciences Partners |
U3 has been developing antibody-based targeted cancer therapeutics. Its lead products are nearing the clinic. |
Comments